Fusion Pharmaceuticals Inc (FUSN)

NASDAQ
2.100
-0.020(-0.94%)
After Hours
2.040
-0.060(-2.857%)
- Real-time Data
  • Volume:
    207,405
  • Day's Range:
    2.060 - 2.149
  • 52 wk Range:
    1.990 - 9.500
Unusual trading volume

FUSN Overview

Prev. Close
2.1
Day's Range
2.06-2.149
Revenue
2.07M
Open
2.1
52 wk Range
1.99-9.5
EPS
-1.75
Volume
207,405
Market Cap
90.34M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
51,054
P/E Ratio
-1.22
Beta
-0.04
1-Year Change
-74.79%
Shares Outstanding
43,019,620
Next Earnings Date
Nov 15, 2022
What is your sentiment on Fusion Pharma?
or
Market is currently closed. Voting is open during market hours.

Fusion Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Fusion Pharmaceuticals Inc Company Profile

Fusion Pharmaceuticals Inc Company Profile

Employees
51

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong BuyStrong SellSellStrong Sell
Technical IndicatorsNeutralStrong BuyStrong BuyStrong SellStrong Sell
SummaryNeutralStrong BuyStrong SellStrong SellStrong Sell
  • Interesting company, with a very large market key product. Spin off from government and a University, so it is much more substantive a company than typical start ups. Trading below ipo price, looks like a nice discount for a longer term hold.
    0